

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

| SUBMISSION TYPE: | NEW ASSIGNMENT | | | | | | | | | | | | | | |
|--|-----------------------|---------------|----------------------|---------------------|-----------------------|-------------------|------------|--------------------|------------|----------------|------------|------------------|------------|----------------|------------|
| NATURE OF CONVEYANCE: | ASSIGNMENT | | | | | | | | | | | | | | |
| CONVEYING PARTY DATA | | | | | | | | | | | | | | | |
| <table border="1"> <thead> <tr> <th>Name</th> <th>Execution Date</th> </tr> </thead> <tbody> <tr> <td>Ko RII</td> <td>07/25/2013</td> </tr> <tr> <td>Kazuo SAKURAI</td> <td>07/17/2013</td> </tr> <tr> <td>Masakazu KOBAYASHI</td> <td>07/31/2013</td> </tr> <tr> <td>Hironori ANDO</td> <td>07/19/2013</td> </tr> <tr> <td>Sadaharu HIGUCHI</td> <td>07/31/2013</td> </tr> <tr> <td>Shiro TAKAHARA</td> <td>07/22/2013</td> </tr> </tbody> </table> | | Name | Execution Date | Ko RII | 07/25/2013 | Kazuo SAKURAI | 07/17/2013 | Masakazu KOBAYASHI | 07/31/2013 | Hironori ANDO | 07/19/2013 | Sadaharu HIGUCHI | 07/31/2013 | Shiro TAKAHARA | 07/22/2013 |
| Name | Execution Date | | | | | | | | | | | | | | |
| Ko RII | 07/25/2013 | | | | | | | | | | | | | | |
| Kazuo SAKURAI | 07/17/2013 | | | | | | | | | | | | | | |
| Masakazu KOBAYASHI | 07/31/2013 | | | | | | | | | | | | | | |
| Hironori ANDO | 07/19/2013 | | | | | | | | | | | | | | |
| Sadaharu HIGUCHI | 07/31/2013 | | | | | | | | | | | | | | |
| Shiro TAKAHARA | 07/22/2013 | | | | | | | | | | | | | | |
| RECEIVING PARTY DATA | | | | | | | | | | | | | | | |
| <table border="1"> <tr> <td>Name:</td> <td>NapaJen Pharma, Inc.</td> </tr> <tr> <td>Street Address:</td> <td>533 Airport Boulevard</td> </tr> <tr> <td>Internal Address:</td> <td>#527</td> </tr> <tr> <td>City:</td> <td>Burlingame</td> </tr> <tr> <td>State/Country:</td> <td>CALIFORNIA</td> </tr> <tr> <td>Postal Code:</td> <td>94010</td> </tr> </table> | | Name: | NapaJen Pharma, Inc. | Street Address: | 533 Airport Boulevard | Internal Address: | #527 | City: | Burlingame | State/Country: | CALIFORNIA | Postal Code: | 94010 | | |
| Name: | NapaJen Pharma, Inc. | | | | | | | | | | | | | | |
| Street Address: | 533 Airport Boulevard | | | | | | | | | | | | | | |
| Internal Address: | #527 | | | | | | | | | | | | | | |
| City: | Burlingame | | | | | | | | | | | | | | |
| State/Country: | CALIFORNIA | | | | | | | | | | | | | | |
| Postal Code: | 94010 | | | | | | | | | | | | | | |
| PROPERTY NUMBERS Total: 1 | | | | | | | | | | | | | | | |
| <table border="1"> <thead> <tr> <th>Property Type</th> <th>Number</th> </tr> </thead> <tbody> <tr> <td>Application Number:</td> <td>14001694</td> </tr> </tbody> </table> | | Property Type | Number | Application Number: | 14001694 | | | | | | | | | | |
| Property Type | Number | | | | | | | | | | | | | | |
| Application Number: | 14001694 | | | | | | | | | | | | | | |
| CORRESPONDENCE DATA | | | | | | | | | | | | | | | |
| <p>Fax Number: 2163639001 <i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i></p> <p>Phone: 216.363.9000 Email: uspto@faysharpe.com Correspondent Name: FAY SHARPE LLP Address Line 1: 1228 Euclid Avenue, 5th Floor Address Line 2: The Halle Building Address Line 4: Cleveland, OHIO 44115</p> | | | | | | | | | | | | | | | |
| ATTORNEY DOCKET NUMBER: | LEXI 200004US01 | | | | | | | | | | | | | | |

OP \$40.00 14001694

| | |
|--|-----------------|
| NAME OF SUBMITTER: | Ann M. Skerry |
| Signature: | /Ann M. Skerry/ |
| Date: | 08/27/2013 |
| Total Attachments: 2 source=LEXI-200004US01-Assignment-27AUG13#page1.tif source=LEXI-200004US01-Assignment-27AUG13#page2.tif | |

ASSIGNMENT


The undersigned is/are the named inventor(s) (the "Inventor(s)") on a United States patent application entitled **(NUCLEIC ACID) - POLYSACCHARIDE COMPLEX** (the "Application") for inventions disclosed or claimed therein (the "Invention(s)"), which Application:

- ☐ is being executed concurrently herewith,
- ☐ was first executed on
- ☒ was filed on February 15, 2012, and assigned PCT International Application No. PCT/JP2012/053583, and
- ☒ claims the benefit of JP Application No. 2011-043310, filed February 28, 2011, and PCT International Application No. PCT/JP2011/068265, filed August 10, 2011.

For valuable consideration, the receipt of which is hereby acknowledged, the Inventors hereby sell, assign and transfer to **NapaJen Pharma, Inc.** ("Assignee"), a corporation of the State of California, having a place of business at **#527, 533 Airport Boulevard, Burlingame, CA 94010**, its successors, assigns, nominees or other legal representatives, the full, exclusive, entire worldwide rights, title and interest in, to, and under said invention as described and claimed in said application, including any provisional application(s) from which it claims priority, the same to be held and enjoyed by Assignee for its own use and enjoyment, and for the use and enjoyment of its successors, assigns, nominees, or other legal representatives, to the end of the term or terms for which said Letters Patent are or may be granted, reissued, or extended, as fully and entirely as the same would have been held and enjoyed by Inventor(s) if this assignment and sale had not been made; all of the entire rights, title and interest in and to said invention and said application, and all original and reissued patents granted for said invention, and all divisions, reissues, continuations-in-part, and continuations of said application, including the subject matter of any and all claims which may be obtained in every patent, and the right, where such right can be legally exercised, in Assignee's own name to apply for and obtain patents in countries foreign to the United States, including the full right to claim for any such application the benefits of the International Convention and the Patent Cooperation Treaty as fully and entirely as Inventor(s) could have done if the foreign application had been filed in the names of the Inventor(s), and the entire interest in any Letters Patent which may be granted on any such application in such foreign countries, and Inventor(s) authorize(s) and request(s) the Commissioner of Patents of the United States, and any official of any country or countries foreign to the United States whose duty is to issue patents on applications as aforesaid, to issue the said Letters Patent to Assignee, its successors, assigns, nominees, or other legal representatives, as Assignee and owner of the said entire rights, and Inventor(s) covenant(s) that Inventor(s) has/have the full right to convey the said entire interest herein assigned and that Inventor(s) has/have not executed and will not execute any agreement in conflict herewith, and Inventor(s) will communicate to Assignee, its successors, assigns, nominees, or other legal representatives all facts known to Inventor(s) respecting said invention, whenever requested, and testify in any legal proceedings, sign all lawful papers, execute and deliver all divisional, continuing, and reissue applications, make all rightful oaths or declarations, and do all lawful acts requisite

for the application for such divisional, continuing, or reissue applications, or the procuring thereof, and that if and when Assignee, its successors, assigns, nominees, or other legal representatives desire to file a disclaimer relating thereto, Inventor(s) will, upon request, sign and deliver all lawful papers requisite for the filing of such disclaimer; and

Inventor(s) further covenant(s) and agree(s) that Inventor(s) will, at any time upon request, do everything possible to aid Assignee, its successors, assigns, nominees, or other legal representatives, either in the name of Inventor(s) or Assignee, to apply for, obtain, and enforce proper patent protection for said invention in all countries, according to the International Convention and the Patent Cooperation Treaty, and all the laws and treaties in force, all without further consideration but at the expense of Assignee, its successors, assigns, nominees, or other legal representatives.


Ko Rii


July 25, 2013
Date


Kazuo SAKURAI

July 19, 2013
Date


Masakazu KOBAYASHI


July 31ST, 2013
Date


Hironori ANDO

July 19, 2013
Date


Sadaharu HIGUCHI

July 31ST, 2013
Date


Shiro TAKAHARA

July 22nd, 2013
Date